{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"136"}],"title":"Died (event)"},{"measurements":[{"groupId":"OG000","value":"313"},{"groupId":"OG001","value":"296"}],"title":"Censored, follow-up ended"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Censored, follow-up ongoing"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"438"},{"groupId":"OG001","value":"432"}],"units":"Participants"}],"description":"Censoring was performed using the date of last known contact for those who were alive at the time of analysis.","groups":[{"description":"Subjects received dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.","id":"OG000","title":"Dabrafenib and Trametinib Combination Therapy"},{"description":"Subjects received matching placebos orally for 12 months","id":"OG001","title":"Dabrafenib and Trametinib Placebos"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent-to-Treat (ITT) Population","reportingStatus":"POSTED","timeFrame":"Approximately 10 years","title":"Percentage of Participants With Overall Survival (OS) Events","type":"SECONDARY","unitOfMeasure":"Participants"}